Natixis Advisors
NTLA icon

Natixis Advisors’s Intellia Therapeutics NTLA Stock Holding History

Natixis Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,249
Closed -$274K – 1626
2024
Q2 		$274K Sell
12,249
-199
-2% -$4.74K ﹤0.01% 1539
2024
Q1 		$342K Buy
+12,448
New +$346K ﹤0.01% 1458

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Natixis Advisors's NTLA Position: Q3 2024 in Review

Natixis Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 12,249 shares — an estimated $274K sold.

Natixis Advisors first reported a position in NTLA in Q1 2024 and held it in 2 quarters. The position peaked at $342K in Q1 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Natixis Advisors reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Natixis Advisors sold 12,249 Intellia Therapeutics shares in Q3 2024, an estimated $274K.
  • Natixis Advisors first reported a position in Intellia Therapeutics in Q1 2024 and held it in 2 quarters.
  • Natixis Advisors's Intellia Therapeutics position peaked at $342K in Q1 2024.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Natixis Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.